Pembrolizumab
Monoclonal antibody targets PDCD1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 44 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (42) | US (FDA) | KEYTRUDA | — | 2015-10-02 – 2026-06-12 | fda.gov ↗ |
| Approved | EU (EMA) | Keytruda | — | 2015-07-17 | europa.eu ↗ |
| Approved | US (FDA) | KEYTRUDA | — | 2014-09-04 | fda.gov ↗ |
Trials 2,148 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 040 trials · 1 met primary | ||||||
| Phase 0 | NCT06637306 | Mar 2025 → Mar 2027 expected | triple-negative breast carcinoma | Rima Patel | Recruiting | No outcome recorded |
| Phase 0 | NCT06308913 | Sep 2024 → Oct 2026 expected | head and neck squamous cell carcinoma | University of Wisconsin, Madison | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06204614 | Jun 2024 → Jul 2028 expected | infiltrating bladder urothelial carcinoma | Brigham and Women's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06366451 | May 2024 → Mar 2026 | head and neck squamous cell carcinoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 0 | NCT05916248 | Dec 2023 → Jun 2026 overdue | neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05553782 | Nov 2023 → Apr 2029 expected | head and neck squamous cell carcinoma, salivary gland adenoid cystic carcinoma | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05733715 | May 2023 → Jun 2026 overdue | renal cell carcinoma | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT05916261 | Apr 2023 → Nov 2026 expected | pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05493566 | Nov 2022 → Jan 2027 expected | non-small cell lung carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 0 | NCT05488366 | Aug 2022 → Jun 2025 overdue | soft tissue sarcoma | University of California, Irvine | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06413095 | Jun 2022 → Jun 2023 | head and neck squamous cell carcinoma, soft tissue sarcoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 0 | NCT05204290 | Mar → Oct 2022 | cancer, epidural spinal canal neoplasm | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT05041153 | Feb 2022 → Dec 2026 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04777708 | Oct 2021 → Mar 2023 | hepatocellular carcinoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT04677361 | Oct 2021 → Oct 2023 | non-small cell lung carcinoma, small cell lung carcinoma | Fox Chase Cancer Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT04541108 | Jul 2021 → Dec 2031 expected | cancer | Presage Biosciences | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04581382 | Dec 2020 → Oct 2024 | melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT04265872 | Oct 2020 → Dec 2026 expected | breast cancer | Baylor Research Institute | Recruiting | No outcome recorded |
| Phase 0 | NCT04220892 | Jul 2020 | high grade astrocytic tumor | Jose Carrillo | Withdrawn | No outcome recorded |
| Phase 0 | NCT04188951 | Oct 2019 → Jun 2023 | head and neck neoplasm | Henry Ford Health System | Completed | No outcome recorded |
| Phase 0 | NCT04134325 | Sep 2019 → Apr 2025 overdue | Hodgkins lymphoma | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03694834 | Mar 2019 → Oct 2023 | endometrial cancer | UNC Lineberger Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03832569 | Feb 2019 → Feb 2027 expected | cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03574220 | Feb 2019 → Mar 2020 | non-small cell lung carcinoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03815630 | Feb 2019 → Feb 2020 | neoplasm | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT03815084 | Feb 2019 → Feb 2020 | neoplasm | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT03599453 | Jan 2019 → Sep 2020 | triple-negative breast carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 0 | NCT03153410 | Sep 2018 → Mar 2022 | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | Met primary |
| Phase 0 | NCT03514121 | Mar 2018 → Apr 2021 | breast cancer, endometrial cancer, ovarian cancer | Five Prime Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 0 | NCT03445858 | Feb 2018 → Nov 2023 | adult lymphoma, pediatric lymphoma, refractory malignant neoplasm | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 0 | NCT03395847 | Feb 2018 → Jan 2023 | esophageal adenocarcinoma, gastric carcinoma, gastroesophageal junction adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT03197389 | Jan 2018 → Mar 2020 | triple-negative breast carcinoma | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 0 | NCT03276832 | Dec 2017 → Oct 2019 | cutaneous melanoma, metastatic melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT03291353 | Oct 2017 → Aug 2019 | acute myeloid leukemia | Michael Boyiadzis | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03224871 | Aug 2017 → Jan 2020 | non-small cell lung carcinoma | University of California, Davis | Completed | No outcome recorded |
| Phase 0 | NCT03099564 | Mar 2017 → May 2021 | hepatocellular carcinoma | Hoosier Cancer Research Network | Unknown | No outcome recorded |
| Phase 0 | NCT02981914 | Mar 2017 → Oct 2020 | B-cell non-Hodgkin lymphoma, acute myeloid leukemia, classic Hodgkin lymphoma, myelodysplastic syndrome | University of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT02872025 | Dec 2016 → Mar 2026 overdue | ductal breast carcinoma in situ | Laura Esserman | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02603887 | Jul 2016 → Dec 2017 overdue | smoldering plasma cell myeloma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02728830 | Jun 2016 → Jan 2019 | endometrial cancer, fallopian tube cancer, ovarian carcinoma, peritoneum cancer | AA Secord | Completed | No outcome recorded |
| Phase 1425 trials · 5 met primary · 2 missed | ||||||
| Phase 1 | NCT07217496 | Dec 2026 → Jan 2028 expected | urinary bladder cancer, urothelial carcinoma | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07388550 | Oct 2026 → Jan 2028 expected | post-COVID-19 disorder | National Institute of Neurological Disorders and Stroke (NINDS) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07695311 | Oct 2026 → Oct 2029 expected | Ewing sarcoma, desmoplastic small round cell tumor | Rabi Hanna | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07807345 | Sep 2026 → Feb 2028 expected | breast cancer, colorectal cancer, endometrial cancer, esophageal cancer +4 | Sutro Biopharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07341867 | Aug 2026 → Mar 2028 expected | plasma cell myeloma, triple-negative breast carcinoma | Andrew Hantel, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07244393 | Jul 2026 → Apr 2029 expected | castration-resistant prostate carcinoma | Cellbion Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06724042 | Jun 2026 → Jun 2029 expected | metastatic neoplasm, neoplasm | InSilico Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07687875 | Jun 2026 → Dec 2028 expected | rectal cancer | Henry Smith | Recruiting | No outcome recorded |
| Phase 1 | NCT07199413 | Jun 2026 → Apr 2029 | malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1 | NCT07385846 | Jun 2026 → Jun 2028 expected | glioblastoma | Jennifer Leddon | Not yet recruiting | No outcome recorded |
| Show all 425 trials opens the full record — a long page | ||||||
| Phase 1/2356 trials · 10 met primary · 6 missed | ||||||
| Phase 1/2 | NCT07843550 | Mar → Jul 2027 expected | neoplasm | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07817901 | Nov 2026 → Dec 2027 expected | metastatic melanoma | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07667335 | Oct 2026 → Jul 2029 expected | infiltrating urothelial carcinoma, urinary bladder carcinoma, urothelial carcinoma | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07751042 | Jun 2026 → Jul 2030 expected | neoplasm | Strand Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07552558 | Jun 2026 → Aug 2028 expected | head and neck squamous cell carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07302347 | Jun 2026 → Mar 2029 expected | cutaneous neuroendocrine carcinoma, lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07639450 | Jun 2026 → Aug 2028 expected | cancer | Hefei Xinzhu Biological Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07591597 | May 2026 → Jul 2027 expected | colorectal cancer | National Cancer Center Hospital East | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05806385 | Mar 2026 → Jan 2027 expected | triple-negative breast carcinoma | Texas Tech University Health Sciences Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07327229 | Feb 2026 → Sep 2027 expected | gastroesophageal adenocarcinoma | Antengene Biologics Limited | Recruiting | No outcome recorded |
| Show all 356 trials opens the full record — a long page | ||||||
| Phase 21,073 trials · 37 met primary · 31 missed | ||||||
| Phase 2 | NCT07037004 | Jan 2027 → Oct 2028 expected | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07845786 | Dec 2026 → Jun 2028 expected | non-small cell squamous lung carcinoma | Exelixis | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07603856 | Dec 2026 → Jun 2030 expected | non-small cell lung carcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT07859592 | Dec 2026 → Nov 2030 expected | adenocarcinoma, chemotherapy-induced toxicity | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07840001 | Dec 2026 → Apr 2029 expected | clear cell renal carcinoma | Peter MacCallum Cancer Centre, Australia | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07643519 | Dec 2026 → Feb 2029 expected | urothelial carcinoma | University of Florida | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06863402 | Nov 2026 → Jun 2029 expected | B-cell chronic lymphocytic leukemia, Richter transformation, diffuse large B-cell lymphoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07857486 | Nov 2026 → Feb 2029 expected | triple-negative breast carcinoma | Institut Paoli-Calmettes | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07822373 | Nov 2026 → Nov 2034 expected | infiltrating bladder urothelial carcinoma | University of Utah | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07691476 | Oct 2026 → Oct 2028 expected | nonpapillary renal cell carcinoma | Yonsei University | Not yet recruiting | No outcome recorded |
| Show all 1,073 trials opens the full record — a long page | ||||||
| Phase 2/322 trials · 1 met primary | ||||||
| Phase 2/3 | NCT07572123 | Dec 2026 → Mar 2029 expected | classic Hodgkin lymphoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06624644 | Aug 2025 → Feb 2029 expected | cutaneous melanoma | Linnaeus Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06697301 | May 2025 → Dec 2035 expected | melanoma | Eikon Therapeutics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06923475 | May 2025 → Nov 2028 expected | distal biliary tract carcinoma, hilar cholangiocarcinoma | Amsterdam UMC, location VUmc | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06493552 | Mar 2025 → Sep 2029 expected | urinary bladder carcinoma, urothelial carcinoma | Vasgene Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06513884 | Dec 2024 → Nov 2029 | oropharynx squamous cell carcinoma | Hookipa Biotech GmbH | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT06295731 | May 2024 → May 2029 expected | head and neck squamous cell carcinoma | Inhibrx Biosciences, Inc | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06295809 | Apr 2024 → Mar 2026 | skin neoplasm, squamous cell carcinoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT06236438 | Apr 2024 → Oct 2031 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06276504 | Apr 2024 → Apr 2028 expected | progressive multifocal leukoencephalopathy | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06907602 | Jan 2024 → Dec 2026 expected | esophageal squamous cell carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05595447 | Oct 2022 → Oct 2025 overdue | Hodgkins lymphoma | Hospital Regional de Alta Especialidad del Bajio | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05255302 | May 2022 → May 2025 overdue | non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05322187 | Apr 2022 → Sep 2023 | childhood malignant neoplasm, hepatoblastoma, transitional cell neoplasm | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05096663 | Mar 2022 → Jun 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04969861 | Mar → Apr 2022 | head and neck cancer | Nektar Therapeutics | Terminated | No outcome recorded |
| Phase 2/3 | NCT04534205 | Jan 2021 → Aug 2028 expected | head and neck squamous cell carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04750083 | Sep 2020 → Sep 2022 | non-small cell lung carcinoma | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT04093167 | May 2020 → Dec 2026 expected | lung cancer | Canadian Cancer Trials Group | Recruiting | Met primary |
| Phase 2/3 | NCT04322617 | Mar 2020 → Mar 2028 expected | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03755739 | Nov 2018 → Nov 2033 expected | breast cancer, cervical cancer, colorectal cancer, head and neck cancer +6 | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01905657 | Aug 2013 → Sep 2015 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3192 trials · 35 met primary · 37 missed | ||||||
| Phase 3 | NCT07689240 | Feb 2027 → Jan 2032 expected | nonpapillary renal cell carcinoma, renal cell adenocarcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07867002 | Oct 2026 → Oct 2032 expected | endometrium adenocarcinoma | UNC Lineberger Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07509099 | Sep 2026 → Sep 2031 expected | head and neck squamous cell carcinoma | Ji Dongmei | Recruiting | No outcome recorded |
| Phase 3 | NCT07684599 | Sep 2026 → Jul 2029 expected | endometrial cancer | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07809256 | Sep 2026 → Aug 2028 expected | non-small cell lung carcinoma | EuroCityClinic LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07750158 | Aug 2026 → Apr 2030 expected | colorectal cancer | Exelixis | Recruiting | No outcome recorded |
| Phase 3 | NCT07178730 | Jun 2026 → Mar 2033 expected | triple-negative breast carcinoma | West German Study Group | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07673887 | Jun 2026 → Feb 2031 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07660094 | Jun 2026 → Oct 2031 expected | non-small cell lung carcinoma | Candel Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07566156 | May 2026 → Mar 2030 expected | urinary bladder neoplasm, urothelial carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Show all 192 trials opens the full record — a long page | ||||||
| Phase 413 trials | ||||||
| Phase 4 | NCT07801027 | Nov 2026 → Jan 2030 expected | biliary tract cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, uterine cervix neoplasm | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07574047 | Sep 2026 → Jun 2030 expected | melanoma | Swiss Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07645625 | May 2026 → May 2030 expected | cervical cancer | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase 4 | NCT07010393 | Jul 2025 → Dec 2027 expected | thyroid tumor | Fujian Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06764095 | Jan 2025 → Jul 2028 expected | bladder transitional cell carcinoma, renal pelvis/ureter urothelial carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06550453 | Sep 2024 → Jan 2025 overdue | colorectal carcinoma | yangjianjun | Recruiting | No outcome recorded |
| Phase 4 | NCT06031233 | Sep 2023 → Jul 2028 expected | — | Isala | Recruiting | No outcome recorded |
| Phase 4 | NCT05203172 | Jul 2022 → Jul 2029 expected | cancer | Pfizer | Recruiting | No outcome recorded |
| Phase 4 | NCT04489888 | Oct 2020 → Feb 2023 | head and neck squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT04554524 | Aug 2020 → Jul 2024 | combined thymoma | Tang-Du Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03891979 | Jun 2019 → Jun 2020 | malignant pancreatic neoplasm | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT03715205 | Jan 2019 → Aug 2024 | melanoma, non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT03134456 | May 2018 → Jul 2019 | non-small cell lung carcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase not applicable24 trials | ||||||
| — | NCT07343596 | Apr 2026 → Dec 2027 expected | oral cavity cancer | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| — | NCT07067450 | Jul 2025 → Dec 2026 expected | esophageal squamous cell carcinoma | Sichuan University | Not yet recruiting | No outcome recorded |
| — | NCT06643910 | Oct 2024 → Aug 2026 overdue | non-small cell lung carcinoma | BioSyngen Pte Ltd | Not yet recruiting | No outcome recorded |
| — | NCT06549855 | Oct 2024 → Jul 2029 expected | endometrial cancer, endometrioid adenocarcinoma | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06341478 | Mar 2024 → Mar 2026 overdue | urinary bladder cancer | IRCCS San Raffaele | Recruiting | No outcome recorded |
| — | NCT06676293 | Aug 2023 → Apr 2024 | nasopharyngeal carcinoma | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT05352165 | Jan 2023 → Dec 2024 | — | Shanghai Minimally Invasive Surgery Center | Unknown | No outcome recorded |
| — | NCT05339581 | May 2022 → Dec 2023 | hepatocellular carcinoma, portal vein thrombosis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT07428252 | Mar 2022 → Mar 2024 overdue | metastatic melanoma | Institute of Oncology Ljubljana | Active not recruiting | No outcome recorded |
| — | NCT07422779 | Mar 2022 → Mar 2027 expected | metastatic melanoma, skin cancer | Institute of Oncology Ljubljana | Recruiting | No outcome recorded |
| — | NCT05368207 | Dec 2021 → Oct 2025 | hypercalcemic type ovarian small cell carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| — | NCT05047094 | Nov 2021 → Dec 2026 expected | head and neck squamous cell carcinoma, skin cancer | Alpha Tau Medical LTD. | Recruiting | No outcome recorded |
| — | NCT04801966 | Sep 2021 → Dec 2022 | cancer | Peter MacCallum Cancer Centre, Australia | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT05902260 | Jul 2021 → Apr 2024 | non-small cell lung carcinoma | Joachim Aerts, MD PhD | Completed | No outcome recorded |
| — | NCT04793815 | May 2021 → Jun 2023 | non-small cell lung carcinoma | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| — | NCT04393883 | Apr 2021 → Jul 2022 | non-small cell lung carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05745233 | Jan 2021 → Dec 2026 expected | peritoneal neoplasm | China Medical University Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT04425226 | Aug 2020 → Dec 2022 | hepatocellular carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03769129 | Nov 2018 → Nov 2026 expected | non-small cell lung carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| — | NCT03035890 | Jan 2017 → Jun 2022 | non-small cell lung carcinoma | West Virginia University | Completed | No outcome recorded |
| — | NCT02760225 | Oct 2016 → Mar 2019 | melanoma, non-small cell lung carcinoma | University Medical Center Groningen | Completed | No outcome recorded |
| — | NCT02658279 | Jan 2016 → Jan 2027 expected | malignant glioma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| — | NCT02489357 | Dec 2015 → Nov 2017 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| — | NCT02194738 | Sep 2014 → Dec 2025 overdue | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT02083484 | — | melanoma | Merck Sharp & Dohme LLC | No longer available | No outcome recorded |
| — | NCT03311542 | — | brain glioma, cutaneous melanoma, glioblastoma | Center Trials & Treatment | No longer available | No outcome recorded |
| — | NCT04135092 | — | — | National Institutes of Health Clinical Center (CC) | No longer available | No outcome recorded |
| Comparator or background therapy487 trials | ||||||
| Phase 0 | NCT06212388 Comparator | Jan 2024 → Oct 2027 expected | melanoma | Xijing Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05589961 Background | Oct 2022 → Jul 2024 | glioblastoma | The Second Hospital of Hebei Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT05358938 Background | Jun 2022 → Oct 2024 overdue | cutaneous melanoma, cutaneous neuroendocrine carcinoma, skin squamous cell carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03371992 Background | Mar 2018 → Dec 2020 | non-small cell lung carcinoma | Nilogen Oncosystems | Unknown | No outcome recorded |
| Phase 1 | NCT04266730 Background | May → Jun 2027 | head and neck squamous cell carcinoma, non-small cell squamous lung carcinoma | UNC Lineberger Comprehensive Cancer Center | Suspended | No outcome recorded |
| Show all 487 trials opens the full record — a long page | ||||||
Press releases naming this drug 915 releases
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 2,643 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pembrolizumab | “The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and...” NCT06307093 ↗2582“1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗ “Standard of Care Drugs (at investigator's discretion) may include: pembrolizumab, nivolumab, cemiplimab, durvalumab, dostarlimab, avelumab, and atezolizumab, or other immune...” NCT07224971 ↗ “All patients will receive a one-cycle lead-in of carboplatin (with or without) paclitaxel followed by three cycles of carboplatin, paclitaxel, and pembrolizumab prior to...” NCT05952453 ↗ “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗ “Successful organoids undergo drug sensitivity testing against a predefined panel of drugs (Gemcitabine + Cisplatin,Gemcitabine + Oxaliplatin,Durvalumab + Gemcitabine +...” NCT07351591 ↗ “This investigator driven pilot study will examine the safety and biological effects of combining MK-3475 (Pembrolizumab) an antibody targeted against the anti-programmed cell...” NCT02303366 ↗ “A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage...” NCT06268613 ↗ “IAM1363 monotherapy OR IAM1363 in combination with capecitabine + trastuzumab OR IAM1363 in combination with capecitabine + zanidatamab OR IAM1363 in combination with T-Dxd OR...” NCT06253871 ↗ “Medical therapy is the continuation of the immune-based combo for mRCC including one of the available options among axitinib + pembrolizumab or cabozantinib + nivolumab or...” NCT06903312 ↗ “The anti-PD-1 agent, pembrolizumab, received recent FDA accelerated approval for the use in patients with metastatic MSI-H or dMMR solid tumors that have progressed following...” NCT04001101 ↗ |
| Known as | 1374853-91-4 | “1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗ |
| Known as | Coformulated favezelimab/pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05845814 ↗ |
| Known as | Coformulated vibostolimab/pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05845814 ↗ |
| Known as | Coformulation favezelimab/pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05342636 ↗ |
| Known as | Keytruda | “The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and...” NCT06307093 ↗167“1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗ “The primary objectives of this study are to evaluate the safety and tolerability of BDB018 in monotherapy and in combination with pembrolizumab (Keytruda) in subjects with...” NCT04840394 ↗ “Pembrolizumab (Keytruda®) is a humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting...” NCT04244552 ↗ “The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the...” NCT05033756 ↗ “The main purpose of this study is to assess the safety, tolerability and anti-tumor activity of the experimental study drug pembrolizumab (also known as Keytruda or MK-3475) in...” NCT03087760 ↗ “A phase II trial investigating the therapeutic effect of neoadjuvant programmed cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to surgery...” PMID 33529989 ↗ Jan 2021 “The primary objective of ELOS is to compare laryngectomy-free survival (LFS) achieved by adding KEYTRUDA® (pembrolizumab) to standard treatment and LFS after standard treatment...” NCT06137378 ↗ “This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in...” NCT06532812 ↗ “Pembrolizumab is an investigational drug (also known as Keytruda), which has been approved by the FDA for use in certain types of skin cancer (melanoma), and for use in certain...” NCT02987998 ↗ “Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint...” NCT07190027 ↗ |
| Known as | Keytruda (pembrolizumab) | “Keytruda® (pembrolizumab)” NCT04777851 ↗ |
| Known as | KEYTRUDA(R) | “Pembrolizumab (KEYTRUDA(R))” NCT03412877 ↗1“Pembrolizumab (KEYTRUDA(R))” NCT04536922 ↗ |
| Known as | Keytruda-EU | “European Union (EU)-authorized pembrolizumab (Keytruda-EU)” NCT06153238 ↗ |
| Known as | Keytruda-US | “Food and Drug Administration (FDA)-licensed pembrolizumab (Keytruda-US)” NCT06153238 ↗ |
| Known as | Keytruda/MK-3475 (Pembrolizumab) | “Keytruda/MK-3475 (Pembrolizumab)” NCT05832827 ↗ |
| Known as | KeytrudaTM | “KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma” NCT03114280 ↗1“KeytrudaTM (pembrolizumab) has been approved in the United States for the treatment of patients with unresectable or metastatic melanoma” NCT03879174 ↗ |
| Known as | lambrolizumab | “1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗3“Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy.” NCT04857164 ↗ “Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy.” NCT04999800 ↗ “Lambrolizumab” NCT03918499 ↗ |
| Known as | MK-3475 | “The purpose of this study is to assess the safety and efficacy of Anlotinib (AL3818) combined with pembrolizumab (MK-3475) in treatment-naïve adults with no prior systemic...” NCT04164745 ↗97“1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗ “The study design initially included two treatment cohorts, with the PD-L1 negative/unknown cohort being treated with the HER2CLIMB regimen with the addition of pembrolizumab...” NCT04789096 ↗ “Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block...” NCT03082534 ↗ “This is a phase II, single arm, open-label, interventional trial of pembrolizumab (MK-3475) in patients with osteosarcoma who have experienced disease relapse or progression...” NCT03013127 ↗ “The main purpose of this study is to assess the safety, tolerability and anti-tumor activity of the experimental study drug pembrolizumab (also known as Keytruda or MK-3475) in...” NCT03087760 ↗ “A phase II trial investigating the therapeutic effect of neoadjuvant programmed cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to surgery...” PMID 33529989 ↗ Jan 2021 “A Phase II Study of Perioperative mFOLFOX (Fluorouracil, Leucovorin, and Oxaliplatin) Chemotherapy Plus Pembrolizumab(MK-3475) Combination in Patients With Potentially...” NCT03488667 ↗ “The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients...” NCT02305186 ↗ “A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination With Pembrolizumab (MK-3475) in...” NCT03739138 ↗ “Pembrolizumab (formerly MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction...” NCT03051672 ↗ |
| Known as | MK-3475, Keytruda | “MK-3475, Keytruda” NCT02287428 ↗ |
| Known as | MK-3475/pembrolizumab (KEYTRUDA) | “MK-3475/pembrolizumab (KEYTRUDA®)” NCT02587455 ↗ |
| Known as | MK-3745 | “The purpose of this study is to determine the feasibility and evaluate the safety of delivering chemoradiotherapy, the usual approach to non-small cell lung cancer, in...” NCT02987998 ↗ |
| Known as | PBZ | “This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC).” NCT03272334 ↗ |
| Known as | PEM | “Here, we present phase I safety results from an open-label, phase I/II study of pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) triplet therapy in advanced, B-Raf...” PMID 34655839 ↗ Oct 20211“pembrolizumab (PEM)” NCT04657991 ↗ |
| Known as | pembro | “To explore the overall response rate (ORR) per RECIST 1.1 as assessed by investigators in subjects with refractory small cell lung cancer treated with pembrolizumab (Pembro)...” NCT03253068 ↗9“The purpose of this study is to determine the efficacy and safety of pembrolizumab (pembro, MK-3475) with or without chemotherapy versus chemotherapy alone” NCT02853305 ↗ “Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5.” NCT05222087 ↗ “Enfortumab vedotin (EV) and pembrolizumab (Pembro) individually have shown a survival benefit in urothelial cancer in second-line + la/mUC settings.” PMID 37369081 ↗ Jun 2023 “Participants receive pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles” NCT03515837 ↗ “The phase Ib/II KEYMAKER-U03 substudy 03A (NCT04626479) investigated novel pembrolizumab (pembro)-based regimens in this setting.” PMID 41115468 ↗ Oct 2025 “pembrolizumab (pembro) will be administered via intravenous (IV) infusion” NCT03010176 ↗ “pembrolizumab (pembro or MK-3475) with or without bevacizumab” NCT03813394 ↗ “200 mg Pembrolizumab (pembro) on day 1 of each cycle” NCT07021989 ↗ “Pembrolizumab (PEMBRO) + Chemotherapy” NCT05502237 ↗ |
| Known as | Pembrolizumab (KEYTRUDA) | “Pembrolizumab (KEYTRUDA®)” NCT05277402 ↗3“Pembrolizumab (Keytruda®)” NCT05508737 ↗ “Pembrolizumab (KEYTRUDA®)” NCT04648202 ↗ “pembrolizumab (KEYTRUDA),” NCT03009058 ↗ |
| Known as | Pembrolizumab (Keytruda, MSD China) | “Pembrolizumab (Keytruda, MSD China)” NCT03895970 ↗ |
| Known as | pembrolizumab (MK-3475) | “pembrolizumab (MK-3475)” NCT06125197 ↗ |
| Known as | Pembrolizumab 25mg/mL (MK-3475) | “Pembrolizumab 25mg/mL (MK-3475)” NCT04219254 ↗ |
| Known as | Pembrolizumab and Chemotherapy drugs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04547504 ↗ |
| Known as | Pembrolizumab Injection | “Pembrolizumab Injection [Keytruda]” NCT04550624 ↗1“Pembrolizumab injection” NCT05809336 ↗ |
| Known as | pembrolizumab(Merck & Co., Inc.) | “pembrolizumab(Merck & Co., Inc.)” NCT03736330 ↗ |
| Known as | Pembrolizumab/vibostolimab coformulation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02625961 ↗ |
| Known as | RPH-075 | “The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and...” NCT06307093 ↗ |
| Known as | SCH 900475 | “1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with...” NCT04418219 ↗4“MK-3475 (previously known as SCH 900475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the...” NCT02636010 ↗ “MK-3475 (previously known as SCH 900475) is a potent and highly-selective humanized mAb of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and...” NCT02129556 ↗ “A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined With Chemotherapy as a First-line Treatment for Non-Small Cell Lung...” NCT03664024 ↗ “SCH 900475” NCT03918499 ↗ |
| Action | Inhibit | “anti-PD-1 antibody” NCT01174121 ↗ |
| Modality | Monoclonal antibody | “Pembrolizumab is a potent, humanized, monoclonal anti-programmed death 1 antibody” PMID 31395089 ↗ Aug 2019 |
| Route | Intravenous | “Pembrolizumab: 200mg IV cycles 1,4,7,10” NCT01042379 ↗ |
| Target | PDCD1 | “the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab” PMID 27138582 ↗ May 2016 |